carboplatin + ipilimumab + nivolumab + pemetrexed

This is a combination therapy consisting of carboplatin (a platinum-based chemotherapy agent), ipilimumab (a CTLA-4 inhibitor), nivolumab (a PD-1 inhibitor), and pemetrexed (a folate analog). The combination is used primarily for the treatment of metastatic non-small cell lung cancer (NSCLC). This regimen combines traditional chemotherapy with dual immune checkpoint inhibition, providing a multi-modal approach to cancer treatment. The combination has shown significant improvement in overall survival compared to chemotherapy alone, with durable responses observed regardless of tumor PD-L1 expression or histology.